LLY

1,152.41

-2.04%↓

JNJ

231.8

-0.62%↓

ABBV

223.9

-0.76%↓

UNH

410.6

+2.54%↑

MRK

118.89

-2.67%↓

LLY

1,152.41

-2.04%↓

JNJ

231.8

-0.62%↓

ABBV

223.9

-0.76%↓

UNH

410.6

+2.54%↑

MRK

118.89

-2.67%↓

LLY

1,152.41

-2.04%↓

JNJ

231.8

-0.62%↓

ABBV

223.9

-0.76%↓

UNH

410.6

+2.54%↑

MRK

118.89

-2.67%↓

LLY

1,152.41

-2.04%↓

JNJ

231.8

-0.62%↓

ABBV

223.9

-0.76%↓

UNH

410.6

+2.54%↑

MRK

118.89

-2.67%↓

LLY

1,152.41

-2.04%↓

JNJ

231.8

-0.62%↓

ABBV

223.9

-0.76%↓

UNH

410.6

+2.54%↑

MRK

118.89

-2.67%↓

Inicio・Lista de Acciones・Compugen Ltd

Compugen Ltd

Abierto

2.07 -0.48

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

Máximo

2.09

Métricas clave
By Trading Economics
Ingresos	-65M -7.7M
Ventas	-65M 2.2M
P/B Media del Sector	6.474 49.888
BPA	-0.08
Margen de beneficios	-352.436
Empleados	75
EBITDA	-64M -7.7M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+138.1% upside

Dividendos
By Dow Jones
Próximas Ganancias	5 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-38M 233M
Apertura anterior	2.55
Cierre anterior	2.07

Compugen Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

8 jun 2026, 22:20 UTC

Adquisiciones, fusiones, absorciones

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 jun 2026, 15:41 UTC

Principales Movimientos del Mercado

American Battery Shares Jump on Energy Department Victory

8 jun 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 jun 2026, 23:37 UTC

Charlas de Mercado

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 jun 2026, 23:25 UTC

Charlas de Mercado

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 jun 2026, 23:25 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

8 jun 2026, 21:57 UTC

Adquisiciones, fusiones, absorciones

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 jun 2026, 21:56 UTC

Adquisiciones, fusiones, absorciones

Salesforce Agrees to Buy m3ter

8 jun 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

8 jun 2026, 19:22 UTC

Charlas de Mercado

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 jun 2026, 19:01 UTC

Charlas de Mercado

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 jun 2026, 18:52 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

8 jun 2026, 18:52 UTC

Charlas de Mercado

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 jun 2026, 18:17 UTC

Charlas de Mercado

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 jun 2026, 17:32 UTC

Charlas de Mercado

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 jun 2026, 17:29 UTC

Charlas de Mercado

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 jun 2026, 17:29 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 jun 2026, 16:55 UTC

Adquisiciones, fusiones, absorciones

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 jun 2026, 16:54 UTC

Adquisiciones, fusiones, absorciones

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 jun 2026, 16:40 UTC

Charlas de Mercado

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 jun 2026, 16:31 UTC

Charlas de Mercado

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 jun 2026, 16:27 UTC

Charlas de Mercado

Mexican Inflation Seen Easing in May -- Market Talk

8 jun 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

8 jun 2026, 16:03 UTC

Adquisiciones, fusiones, absorciones

Orange Bought Stake From Lorca

8 jun 2026, 16:01 UTC

Adquisiciones, fusiones, absorciones

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 jun 2026, 16:01 UTC

Adquisiciones, fusiones, absorciones

Orange Acquires 100% Ownership of MasOrange

8 jun 2026, 15:58 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

8 jun 2026, 15:58 UTC

Charlas de Mercado

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 jun 2026, 15:55 UTC

Charlas de Mercado

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 jun 2026, 15:41 UTC

Charlas de Mercado

Gold Falls Below 200-Day Moving Average -- Market Talk

Comparación entre iguales

Cambio de precio

Compugen Ltd previsión

Precio Objetivo

By TipRanks

138.1% repunte

Estimación a 12 Meses

Media 5 USD 138.1%

Máximo 6 USD

Mínimo 4 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Compugen Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

Comprar

Mantener

Vender

De acuerdo con 3 analistas que ofrecen calificaciones bursátiles a para Compugen Ltd Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.